Metrics as of 10/13/2026, 06:48 PM (Berlin time), refresh in progress.
Praxis Precision Medicines Stock
Praxis Precision Medicines, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Marcio Silva De'Souza
- Employees
- 168
- Market cap
- $6.8 B
- IPO
- 16/10/2020
Praxis Precision Medicines, Inc. is a biopharmaceutical firm in the biotechnology industry headquartered in Boston, US. Operating at the clinical stage, the company focuses on developing innovative treatments for central nervous system (CNS) conditions stemming from imbalances in neuronal activity. The primary…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Praxis Precision Medicines stock: price history
1D
-3.2%
1W
-13.1%
1M
-27.3%
6M
-29.2%
YTD
-17.4%
1Y
+364.9%
2Y
+274.4%
5Y
-18.2%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~7% weaker price swings than usual
Ask the agents about Praxis Precision Medicines
Analyst assessment of Praxis Precision Medicines
PRICE TARGET LOW
US$162.00
CONSENSUS
US$603.83
MEDIAN
US$575.00
PRICE TARGET HIGH
US$1,201.00
0
STRONG BUY
14
BUY
3
HOLD
1
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 06/10/2026
Praxis Precision Medicines stock metrics
P/E
-18.79
P/B
5.29
EV/EBITDA
-18.61
RETURN ON EQUITY
-6.2%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.7%
FLOAT SHARES
26,116,274
AVG. DAILY VOLUME (30D)
449,099
Insider transactions (SEC)
Souza Marcio
Souza Marcio
DeSimone Jill
DeSimone Jill
DeSimone Jill
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.2%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Praxis Precision Medicines stock
What does Praxis Precision Medicines do?
Praxis Precision Medicines, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Marcio Silva De'Souza, the company employs around 168 people.
The IPO was on 16/10/2020; the stock trades on NASDAQ under the ticker PRAX.
What do analysts say about Praxis Precision Medicines stock?
18 analysts rate the stock, the consensus is Buy (as of 06/10/2026).
The average price target is US$603.83, ranging from US$162.00 to US$1,201.00, with a median of US$575.00.
This is an external assessment, not a statement by Market Jury.
When does Praxis Precision Medicines report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -7% stronger than usual.
Does Praxis Precision Medicines pay a dividend?
No, Praxis Precision Medicines currently does not pay a dividend.
Which stocks are comparable to Praxis Precision Medicines?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Praxis Precision Medicines stock analyzed?
Clicking "Analyze stock" lets five strategies assess Praxis Precision Medicines against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.